Help! Please Register



  Mycoses

  Introduction
  Human
  Veterinary
  Environmental
   Industrial
  Agricultural
  MSG


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank


  Drugs

  Introduction
  Medical
  Veterinary
  Environmental
   Industrial
  Agricultural


  Laboratory

  Introduction
  Susceptibility
  MIC Database
  Procedures
  Histopathology


  Education &
  Tools

  Introduction
  Abbreviations
  Links
  CME
  Conference
   Highlights
  Bibliography
  Glossary
  Good Books
  Events Calendar


  About Us

  Introduction
  Our Mission
  Editorial Board
  Editorial Staff
  Supporters
  Contributors
  Legal Stuff
  Privacy Policy
  Kudos


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank



This page updated:
1/27/2007 9:23:00 AM


DoctorFungus - All Rights Reserved © 2007 Copyright
& Privacy Policy


Site built and designed for doctorfungus by Webillustrated



You are here: Education & Tools >
Enzon Pharmaceuticals, Inc.

ICHS
Course and Test - take it your way
PDF Course and Test
Help!
000


CME
Course Title:
Case Studies in the Antifungal Treatment of High-Risk Patients
Cryptococcus Infection in a CLL Patient



Mission:

The Goal of the CME program is to plan and deliver high quality education activities for practicing physicians in order to reinforce their past learning and to disseminate new concepts and practices in medicine which may improve patient care for all medical specialties.

Up   
Target Audience:

The audiences to be reached by its program of CME are:

  • Infectious Disease Physicians
  • Hematology Oncologists
  • Transplant Surgeons

    Up   
  • Educational Objectives:

  • Determine how therapeutic choices for invasive fungal infections can be most appropriately employed in high-risk patients.

  • Explore methods to improve patient outcomes, considering antifungal efficacy, spectrum of activity, safety, and cost-effectiveness.

  • Compare and understand the clinical uses of available antifungal agents.

    Up   
  • CME Information:

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Wayne State University School of Medicine and the MedEd Group, LLC.

    The Wayne State University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Wayne State University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    To receive documentation of your participation in this CME activity, complete the newsletter posttest with a passing score of 70% or higher. Full instructions for submission are included on the posttest accompanying this CME newsletter. After passing the posttest, you will be issued a CME certificate of 1.0 credit.

    Up   
    Disclosure Information:

    The disclosure policy of Wayne State University School of Medicine requires that the faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.

  • Pranatharthi Chandrasekar, MD, is a consultant for Enzon Pharmaceuticals, Inc., and has received honoraria/travel expenses, or other financial or material support from Enzon Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co., Inc., and Schering-Plough.

  • Dimitrios P. Kontoyiannis, MD, MSc, ScD, FACP, FIDSA, is on the advisory board of and is a consultant for Merck & Co., Inc., and Schering-Plough. He has received research support from Enzon Pharmaceuticals, Inc., Fujisawa/ Astellas, and Merck & Co., Inc., and has received honoraria/travel expenses or other financial or material support from Enzon Pharmaceuticals, Inc., Fujisawa/Astellas, and Merck & Co., Inc.

    Up   

  • This CME Expires on September 07, 2007; no tests will be accepted after this date.

    This CME activity is supported by an educational grant from Enzon Pharmaceuticals, Inc.

    Up   



    Privacy Policy
    Contact: mycosesstudygroup.org
    Site Contents Copyright © 2007 mycosesstudygroup.org

     





      Home | Image Bank | Lecture Bank | Knowledgebase | Site Map | Contact Us |
    The Fungi | Mycoses | Drugs |
    Laboratory | Education & Tools | About Us

      bttm_banner_indv2_02[1].gif